Xenofon Baraliakos

Q: What Schools Are Affiliated With Xenofon Baraliakos

Xenofon Baraliakos is affiliated with the following schools: University of Cologne, Ruhr University Bochum

Xenofon Baraliakos's AcademicInfluence.com Rankings

Xenofon Baraliakos

Philosophy

#8508

World Rank

#11908

Historical Rank

Logic

#5542

World Rank

#6949

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Xenofon Baraliakos's Degrees

PhD Medicine University of Cologne
Doctorate Medicine University of Cologne

Why Is Xenofon Baraliakos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Xenofon Baraliakos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis (2009) (1281)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (2017) (1140)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (2011) (959)
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group (2009) (781)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. (2015) (728)
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. (2009) (630)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial (2013) (513)
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. (2008) (496)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2017) (476)
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force (2013) (436)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (2020) (433)
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. (2003) (415)
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. (2005) (403)
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice (2015) (390)
Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group (2016) (346)
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. (2009) (314)
Do patients with non‐radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? (2012) (289)
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) (266)
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis (2013) (253)
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes (2007) (235)
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis (2008) (227)
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group (2012) (223)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study (2016) (212)
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort (2017) (203)
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. (2007) (202)
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis (2011) (201)
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. (2005) (199)
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept (2005) (191)
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. (2007) (190)
The Natural Course of Radiographic Progression in Ankylosing Spondylitis — Evidence for Major Individual Variations in a Large Proportion of Patients (2009) (171)
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. (2005) (165)
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography (2013) (162)
Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. (2007) (147)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial (2018) (143)
First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. (2012) (139)
MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group (2019) (134)
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis (2011) (134)
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept (2005) (123)
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab (2005) (120)
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. (2011) (116)
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial (2013) (112)
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study (2018) (99)
Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis (2017) (95)
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial (2018) (94)
MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor (2012) (92)
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis (2016) (90)
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. (2018) (89)
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study (2011) (88)
MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis (2015) (86)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement (2020) (85)
Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. (2009) (85)
High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis (2013) (80)
Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next (2017) (78)
The course of the greater occipital nerve in the suboccipital region: A proposal for setting landmarks for local anesthesia in patients with occipital neuralgia (2006) (77)
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. (2007) (77)
Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. (2012) (76)
Imaging of axial spondyloarthritis including ankylosing spondylitis (2011) (76)
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study (2020) (73)
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2019) (70)
Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort (2017) (69)
Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study (2015) (68)
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study (2021) (67)
Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis (2017) (67)
Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis (2018) (64)
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey (2006) (64)
A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years. (2012) (63)
A stratified model for health outcomes in ankylosing spondylitis (2011) (63)
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial (2020) (60)
Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years (2019) (60)
Magnetic resonance imaging in ankylosing spondylitis (2006) (60)
The involvement of the spine in psoriatic arthritis. (2015) (59)
Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis (2008) (57)
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study (2019) (57)
Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity (2015) (55)
Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years (2013) (53)
Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis (2018) (52)
Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides (2005) (52)
Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? (2007) (52)
The Natural Course of Radiographic Progression in Ankylosing Spondylitis: Differences Between Genders and Appearance of Characteristic Radiographic Features (2011) (50)
EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases (2019) (50)
Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort (2017) (45)
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction (2020) (44)
Hip involvement in ankylosing spondylitis: what is the verdict? (2010) (43)
Classification and Diagnosis of Axial Spondyloarthritis — What Is the Clinically Relevant Difference? (2015) (42)
Biologic Therapies for Spondyloarthritis: What Is New? (2012) (41)
Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis (2017) (41)
Treatment of ankylosing spondylitis and other spondyloarthritides (2009) (40)
Therapy of ankylosing spondylitis – a review. Part I: Conventional medical treatment and surgical therapy (2005) (40)
Detection of Erosions in Sacroiliac Joints of Patients with Axial Spondyloarthritis Using the Magnetic Resonance Imaging Volumetric Interpolated Breath-hold Examination (2019) (39)
Emerging drugs for the treatment of axial and peripheral spondyloarthritis (2015) (39)
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients (2018) (38)
Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? (2012) (37)
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years (2016) (35)
Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials (2015) (32)
Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time (2017) (31)
Structural progression in axial spondyloarthritis. (2020) (31)
What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis (2019) (31)
Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab (2016) (30)
Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review (2020) (30)
Causes of pain in patients with axial spondyloarthritis. (2017) (29)
The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA–B27 Status? (2020) (29)
Diagnostic value of MRI features of sacroiliitis in juvenile spondyloarthritis. (2015) (29)
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies (2021) (29)
ASAS definition for sacroiliitis on MRI in SpA: applicable to children? (2017) (28)
Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis (2019) (28)
Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study (2016) (27)
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update (2022) (27)
Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. (2020) (27)
The Role of Imaging in Diagnosing Axial Spondyloarthritis (2018) (27)
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS) (2020) (26)
Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies (2020) (26)
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies (2018) (25)
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis (2017) (24)
Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR (2019) (24)
Diagnositic value of pelvic enthesitis on MRI of the sacroiliac joints in enthesitis related arthritis (2015) (24)
Secukinumab (AIN457) in the treatment of ankylosing spondylitis (2016) (23)
Data-Driven Definitions for Active and Structural MRI Lesions in the Sacroiliac Joint in Spondyloarthritis and their Predictive Utility. (2021) (23)
Assessment of spinal pain. (2014) (22)
Response to: ‘Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al’ by Wei et al (2020) (22)
Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis (2014) (21)
Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging (2011) (21)
Magnetic resonance imaging in spondyloarthropathies. (2006) (21)
OP0235 SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL (2019) (20)
Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype (2013) (20)
Dual‐phase hybrid 18F‐Fluoride Positron emission tomography/MRI in ankylosing spondylitis: Investigating the link between MRI bone changes, regional hyperaemia and increased osteoblastic activity (2018) (20)
OMERACT Magnetic Resonance Imaging Initiative on Structural and Inflammatory Lesions in Ankylosing Spondylitis — Report of a Special Interest Group at OMERACT 10 on Sacroiliac Joint and Spine Lesions (2011) (19)
Imaging of diffuse idiopathic skeletal hyperostosis (DISH) (2020) (19)
Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence (2019) (19)
The ASAS-OMERACT core domain set for axial spondyloarthritis. (2021) (19)
Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations (2019) (19)
Ocular involvement in patients with spondyloarthritis (2017) (19)
Infection and work stress are potential triggers of ankylosing spondylitis (2006) (19)
Imaging of axial spondyloarthritis. New aspects and differential diagnoses. (2018) (19)
Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy (2013) (18)
Anti-TNF-α therapy with infliximab in spondyloarthritides (2010) (18)
Opinion: Perspectives on imaging in axial spondyloarthritis (2013) (16)
Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component (2021) (16)
Imaging in the preclinical phases of rheumatoid arthritis. (2019) (16)
Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. (2013) (16)
Chronic but not inflammatory changes at the Achilles’ tendon differentiate patients with peripheral spondyloarthritis from other diagnoses – Results from a prospective clinical trial (2017) (16)
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study (2021) (15)
Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis (2015) (15)
Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists’ Evaluations With Radiologists’ Findings (2020) (15)
HLA‐B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study (2019) (15)
Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population? (2020) (15)
Imaging Scoring Methods in Axial Spondyloarthritis. (2016) (15)
The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. (2019) (14)
Anti-TNF-alpha therapy with infliximab in spondyloarthritides. (2010) (14)
The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures (2018) (14)
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data (2022) (14)
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study (2018) (14)
Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab (2016) (14)
Imaging in axial spondyloarthritis: diagnostic problems and pitfalls. (2012) (14)
Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes (2015) (13)
Challenges and Advances in Targeting Remission in Axial Spondyloarthritis (2018) (13)
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis (2019) (13)
Early recognition of patients with axial spondyloarthritis-evaluation of referral strategies in primary care. (2020) (13)
Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities (2018) (12)
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2021) (12)
The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms (2006) (12)
Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica. (2018) (12)
[Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? : Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany]. (2019) (11)
Imaging in axial spondyloarthritis: Changing concepts and thresholds. (2018) (11)
Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression (2020) (11)
Active and chronic sacroiliitis, spondylitis and enthesitis, How specific are imaging findings for axial spondyloarthritis? (2019) (11)
Treat-to-target in axial spondyloarthritis — what about physical function and activity? (2021) (11)
The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study (2019) (10)
OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES (2020) (10)
Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years (2021) (10)
Non-radiographic axial spondyloarthritis: a classification or a diagnosis? (2016) (10)
Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica. (2020) (10)
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial (2022) (10)
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies (2020) (10)
The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis (2015) (10)
Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria (2020) (10)
Current Controversies in Spondyloarthritis: SPARTAN (2010) (10)
Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study (2017) (9)
Is undifferentiated spondyloarthritis a discrete entity? A debate. (2017) (9)
Treat to Target in Axial Spondyloarthritis. (2019) (9)
Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design? (2013) (9)
OP0053 SECUKINUMAB IMPROVES CLINICAL AND IMAGING OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS WITH INADEQUATE RESPONSE TO NSAIDS: WEEK 52 RESULTS FROM THE MAXIMISE TRIAL (2020) (9)
Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) (9)
2019 EULAR points to consider for the assessment of competences in rheumatology specialty training (2020) (9)
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE (2020) (9)
Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus (2016) (9)
Response to: ‘Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Fallon et al (2020) (8)
Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis – the TryCort study (2017) (8)
Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al (2020) (8)
Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists. (2013) (8)
TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases (2021) (8)
Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial (2020) (8)
Non-medical switching from reference to biosimilar etanercept - no evidence for nocebo effect: a retrospective analysis of real-life data. (2021) (8)
264 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis (2019) (8)
Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning (2021) (8)
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews (2020) (8)
Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort (2020) (7)
OP0309 THE ROLE OF IMAGING TO GUIDE INTERVENTIONAL PROCEDURES IN RHEUMATIC AND MUSCULOSKELETAL DISEASES: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR RECOMMENDATIONS (2021) (7)
Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence (2021) (7)
Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study (2020) (7)
Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) (7)
[Evaluation of the trabecular bone score (TBS) in routine clinical care of patients with inflammatory rheumatic and non-inflammatory diseases : Correlation with conventional bone mineral density measurement and prevalence of vertebral fractures]. (2020) (7)
Imaging in Axial Spondyloarthritis. (2017) (7)
FRI0127 Eular Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice (2014) (7)
The role of 18F-FDG positron emission tomography for the diagnosis of vasculitides. (2018) (7)
Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis (2022) (6)
EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19 SUBUNIT OF IL-23, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-52 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES (2021) (6)
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis (2022) (6)
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis (2022) (6)
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial (2022) (6)
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial) (2021) (6)
[Current state, goals and quality standards of outpatient care in rheumatology: position paper of the Professional Association of German Rheumatologists (BDRh)]. (2020) (6)
Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial (2014) (6)
Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis. (2012) (6)
Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. (2020) (6)
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. (2016) (6)
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies (2021) (6)
Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study (2021) (6)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one (2017) (6)
Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype? (2019) (6)
OP0242 Fatty lesions detected on mri scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow (2018) (6)
A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features (2021) (5)
Diagnostic Value of MRI of the Sacroiliac Joints in Juvenile Spondyloarthritis (2016) (5)
Update on imaging in rheumatic diseases. (2018) (5)
The need for comparative data in spondyloarthritis (2019) (5)
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate (2020) (5)
Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years (2005) (5)
Spinal mobility in the cervical and lumbar spine correlates with magnetic resonance imaging findings for inflammatory and structural changes in patients with active ankylosing spondylitis. (2020) (5)
Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis (2022) (5)
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort (2022) (5)
Quantification of Bone Marrow Edema by Magnetic Resonance Imaging Only Marginally Reflects Clinical Neck Pain Evaluation in Rheumatoid Arthritis and Ankylosing Spondylitis (2016) (5)
The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms (2006) (5)
MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group (2022) (5)
Microsurgical nerve root decompression in scoliotic lumbar spines-the relationship between important anatomical structures in correlation to imaging and implications for daily practice: anatomic cadaveric study. (2010) (5)
FRI0101 NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT – NO EVIDENCE FOR A RELEVANT NOCEBO EFFECT – A RETROSPECTIVE ANALYSIS OF REAL-LIFE DATA (2019) (5)
EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs) (2021) (4)
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks (2020) (4)
[German translation and cross-cultural adaptation of the ASAS health index : An ICF-based instrument for documentation of functional ability in patients with ankylosing spondylitis]. (2016) (4)
OP0086 THE DEGREE OF BONE MARROW EDEMA AS DETECTED BY MAGNETIC RESONANCE IMAGING IN THE SACROILIAC JOINTS AND THE SPINE SUSPICIOUS OF AXIAL SPONDYLOARTHRITIS IN THE GENERAL POPULATION IS ASSOCIATED WITH DIFFERENT FACTORS (2020) (4)
Update of imaging in the diagnosis and management of axial spondyloarthritis. (2020) (4)
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials (2022) (4)
What is peripheral spondyloarthritis? Identifying proportion, phenotype and burden in post hoc analysis of the ASAS-PerSpA study. (2022) (4)
THU0211 RADIOGRAPHIC OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE: RESULTS AT 2 YEARS FROM THE SELECT-COMPARE AND SELECT-EARLY STUDIES (2020) (4)
THU0377 IMPACT OF FILGOTINIB ON STRUCTURAL LESIONS IN THE SACROILIAC JOINTS AT 12 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE DOUBLE-BLIND, RANDOMIZED TORTUGA TRIAL (2020) (4)
AB1171 Effects of successive switches of two different biosimilars of etanercept on outcomes in inflammatory rheumatic diseases in daily practice (2020) (4)
Response to ‘Evidence in Support of the Validity of the TNF Brake Hypothesis’ by Maksymowych (2013) (4)
[Imaging of psoriatic arthritis and aspects of radiographic progression]. (2019) (4)
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis (2019) (4)
Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort. (2022) (3)
Instrument selection for the ASAS core outcome set for axial spondyloarthritis (2022) (3)
Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis (2022) (3)
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction (2016) (3)
Spondyloarthropathies: The disease process in axial SpA: what can biomarkers tell us? (2011) (3)
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study (2022) (3)
Learning from the youngsters: ixekizumab in active ankylosing spondylitis (2018) (3)
[Clinical significance of determination of DFS70 antibodies to rule out connective tissue diseases]. (2019) (3)
Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment (2022) (3)
MRI infl ammation at the vertebral unit only marginally predicts new syndesmophyte formation : a multilevel analysis in patients with ankylosing spondylitis (2011) (3)
[Validation of the German translation of the ASAS health index : A questionnaire to assess functioning and health in patients with spondyloarthritis]. (2019) (3)
Disease Modification in Axial Spondyloarthritis (2018) (3)
[Inflammatory spinal diseases: axial spondyloarthritis : Central importance of imaging]. (2017) (3)
Root Joint Involvement in Spondyloarthritis: A Post-hoc Analysis from the International ASAS-PerSpA Study. (2021) (3)
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial (2021) (3)
High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis (2022) (3)
[Magnetic resonance imaging (MRI) diagnostics in axial spondyloarthritis]. (2017) (3)
Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data (2022) (3)
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials (2023) (3)
Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider (2021) (3)
OP0171 Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol (2015) (3)
[MRI examinations for axial and peripheral spondyloarthritis]. (2012) (3)
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe (2020) (3)
FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES (2019) (3)
Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Ramiro et al (2023) (2)
Rheumatologists use different cut offs for disease activity in real life - the experience with Golimumab in ankylosing spondylitis - Subanalysis from the Non-Interventional German GO-NICE study. (2019) (2)
Effects of patient and disease characteristics on global functioning in patients with axial spondyloarthritis in routine care. (2022) (2)
Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé (2022) (2)
Evaluation of Sodium Relaxation Times and Concentrations in the Achilles Tendon Using MRI (2022) (2)
SAT0570 GAPS IN PATIENT SAFETY PERFORMANCE IN PATIENTS WITH IMMUNOSUPPRESSIVE THERAPY: RESULTS OF SCREENING FOR INFECTIONS AND VACCINATION STATUS IN A LARGE REAL-LIFE COHORT (2019) (2)
Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series (2022) (2)
New developments in ankylosing spondylitis—status in 2021 (2021) (2)
Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5-year follow-up data from the ASAS cohort. (2021) (2)
POS0900 SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY (2021) (2)
FRI0317 CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SPINE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION COHORT (2020) (2)
Recognition of spondyloarthritis lesions on magnetic resonance imaging: Results of an educational intervention (2020) (2)
[Imaging in patients with axial spondylarthritis with focus on new bone formation]. (2019) (2)
Unanswered questions in the management of axial spondyloarthritis: an opinion piece (2014) (2)
FRI0312 ANTI-CD74 IGA ANTIBODIES ARE MOST SENSITIVE AND SPECIFIC TO IDENTIFY YOUNG MALE AXIAL SPONDYLOARTHRITIS PATIENTS (2020) (2)
Dopamine receptor 1 expressing B cells exert a proinflammatory role in female patients with rheumatoid arthritis (2022) (2)
Functional MR imaging beyond structure and inflammation—radiographic axial spondyloarthritis is associated with proteoglycan depletion of the lumbar spine (2020) (2)
Engagement process for patients with spondyloarthritis: PANLAR early SpA clinics project — centers of excellence (2021) (2)
[Model curriculum of the German Society for Rheumatology for advanced training in the discipline internal medicine and rheumatology]. (2021) (2)
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS (2021) (2)
P184 Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial (2021) (2)
Changes of immunosuppressive medication because of COVID-19 by patients with chronic inflammatory rheumatic diseases: anxiety was not a major driver. (2021) (2)
THU0278 The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results (2013) (2)
Deep Learning Detects Changes Indicative of Axial Spondyloarthritis at MRI of Sacroiliac Joints. (2022) (2)
Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography? (2022) (2)
The influence of age on the prevalence of inflammatory and structural MRI lesions in the SIJ of patients with and without axSpA. (2022) (2)
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022 (2023) (2)
THU0414 Inter SPA: Sensitivity and Specifity of Autoantibodies against CD74 in Early Axial Spondyloarthritis (2016) (2)
OP0172 Inflammation and fatty degeneration are of similar importance for new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years (2013) (2)
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1 (2021) (2)
Response to: ‘Correspondence on ‘Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?’ by Su et al (2021) (2)
POS0301 NO MAJOR DIFFERENCES BETWEEN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASE WHO UNDERWENT MONO- OR MULTISWITCHING OF BIOSIMILARS IN ROUTINE CARE (PERCEPTION STUDY) (2021) (2)
Spondyloarthritis: The Changing Landscape-Are We There Yet? (2020) (2)
Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis (2022) (2)
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY (2021) (2)
[Threat of a SARS-CoV-2 endemic in a large hospital specialized in rheumatic diseases-relative all clear through consistent testing]. (2021) (2)
THU0234 Long-Term Efficacy of Infliximab in Patients with Ankylosing Spondylitis – Real Life Data Confirm the Potential for Dose Reduction by Stretching Infusion Intervals (2015) (2)
Outcome assessment in axial spondyloarthritis-imaging techniques, their relation to outcomes and their use in clinical trials (2013) (2)
[Imaging of the sacroiliac joints]. (2017) (2)
OP0032 LOCALIZATION AND MORPHOLOGY OF MAGNETIC RESONANCE IMAGING FEATURES OF PATHOLOGIC CHANGES IN THE SACROILIAC JOINTS SUGGESTIVE OF AXIAL SPONDYLOARTHRITIS – A SYSTEMATIC COMPARISON OF PATIENTS AND CONTROLS WITH CHRONIC BACK PAIN (2019) (2)
[Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations]. (2019) (2)
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION? (2020) (1)
FRI0279 High prevalence of anti-CD 74 antibodies with specificity for the class II-associated invariant chain peptide (clip) in patients with axial spondyloarthritis but not in controls (2013) (1)
Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review (2022) (1)
Inflammation and Fatty Degeneration in New Bone Formation in Patients with AS Treated with Anti-TNF Agents (2012) (1)
Dose tapering of biologic agents in patients with rheumatoid arthritis—results from a cohort study in Germany (2020) (1)
FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES (2020) (1)
Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery? (2021) (1)
THU0188 INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1 YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAM (2019) (1)
What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis? (2023) (1)
PROMs for Spondyloarthritis (2016) (1)
Adaptive IoU Thresholding for Improving Small Object Detection: A Proof-of-Concept Study of Hand Erosions Classification of Patients with Rheumatic Arthritis on X-ray Images (2022) (1)
THU0397 Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from a phase 3 extension trial (MEASURE 1) (2017) (1)
Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years (2022) (1)
SAT0135 COMPARISON OF THE EFFICACY AND SAFETY OF TWO BRIDGING SCHEDULES OF PREDNISOLONE IN EARLY ACTIVE RHEUMATOID ARTHRITIS (CORRA): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL (2020) (1)
Tapering bDMARDs in axial SpA — what is the current evidence? (2019) (1)
Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation. (2022) (1)
Effects of Anti–Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective Proof‐of‐Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine (2022) (1)
Letter to the article of Bray T et al: Sacroiliac joint ankylosis in young spondyloarthritis patients receiving biologic therapy: observation of serial MRI scans. (2019) (1)
Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study (2021) (1)
Current Concepts in the Therapy of the Spondyloarthritides (2012) (1)
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes (2022) (1)
Speaker Abstracts (SP01–SP50) (2012) (1)
OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (2019) (1)
Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis (2005) (1)
[Do we still need clinical studies in rheumatology?]. (2016) (1)
THU0361 DIAGNOSTIC PERFORMANCE OF MRI LESIONS IN THE SACROILIAC JOINTS ACCORDING TO UPDATED ASAS LESION DEFINITIONS: A CENTRAL READER ASSESSMENT OF MRI SCANS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS CLASSIFICATION COHORT (2019) (1)
THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB (2020) (1)
Recommendation for the Management of Spondyloarthritis Patients in Kuwait (2020) (1)
Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey (2021) (1)
POS0930 SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS: PREDICTORS OF RESPONSE FROM THE DOUBLE-BLIND, RANDOMISED, PHASE 3B MAXIMISE TRIAL (2021) (1)
OP0045 Clinically Active Non-Radiographic Axial Spondyloarthritis Patients who Initially have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint (2015) (1)
P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses (2021) (1)
Paper #23 The value of capsular shrinkage in the arthroscopic stabilization of the posttraumatic antero-inferior shoulder instability (2003) (1)
25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial (2021) (1)
OP0104 THE IMPACT OF PERSISTENT INFLAMMATORY CHANGES ON PREVALENCE OF FATTY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: 4-YEAR MRI RESULTS FROM RAPID-AXSPA (2020) (1)
Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases (2022) (1)
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial (2022) (1)
AB1245 DAILY MANAGEMENT OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: SELF-MONITORING OF DISEASE ACTIVITY WITH A SMARTPHONE APP IS FEASIBLE – A PROOF OF CONCEPT STUDY (2020) (1)
AB1083 CURRENT PRACTICE AND OPINIONS ON IMAGING-GUIDED INTERVENTIONAL PROCEDURES IN RHEUMATIC AND MUSCULOSKELETAL DISEASES: INTERIM RESULTS OF A MULTINATIONAL MULTIDISCIPLINARY SURVEY TO INFORM EULAR POINTS TO CONSIDER (2020) (1)
SP0060 Eular recommendations for the use of imaging in mechanical low back pain (2018) (1)
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial (2021) (1)
The Efficacy of Short‐Term Bridging Strategies With High‐ and Low‐Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double‐Blind, Randomized, Placebo‐Controlled Trial (2022) (1)
SAT0529 TWO-YEAR PROGRESSION OF FACET JOINT ANKYLOSIS ON WHOLE SPINE LOW-DOSE CT IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: DATA FROM THE SENSITIVE IMAGING OF AXIAL SPONDYLOARTHRITIS (SIAS) COHORT (2019) (1)
Management of Axial Spondyloarthritis – Insights into Upadacitinib (2022) (1)
Reflections on a contemporary European tragedy (2022) (1)
Do NSAIDs affect radiographic progression in axial SpA? (2019) (1)
Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis (2022) (1)
SAT0528 DETECTION OF FACET JOINT ANKYLOSIS ON WHOLE SPINE LOW-DOSE CT IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: DATA FROM THE SENSITIVE IMAGING OF AXIAL SPONDYLOARTHRITIS (SIAS) COHORT (2019) (1)
Different types of structural changes in the sacroiliac joints in axial spondyloarthritis-how important are joint shape variations? (2022) (1)
OP0344 WHICH MAGNETIC RESONANCE IMAGING LESIONS OF THE SACROILIAC JOINTS ARE OF DIAGNOSTIC VALUE FOR AXIAL SPONDYLOARTHRITIS? (2019) (1)
[How well are patients with inflammatory rheumatic diseases protected against measles?] (2020) (1)
Clinically Relevant Deficits in Performance Tests in Patients With Axial Spondyloarthritis (2022) (1)
THU0262 Sclerostin does not predict radiographic progression in patients on anti-tnf therapy – new results from the european ankylosing spondylitis (AS) infliximab cohort (EASIC) (2013) (1)
Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach (2018) (1)
OP0343 LONGITUDINAL ASSESSMENT OF MRI OF THE SACROILIAC JOINTS IN THE ASAS CLASSIFICATION COHORT: EVOLUTION OF DIAGNOSTIC FEATURES AND PREDICTIVE UTILITY FOR AXIAL SPONDYLOARTHRITIS: (2019) (1)
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial (2022) (1)
OP0141 EFFECTS OF FILGOTINIB ON SPINAL LESIONS IN ANKYLOSING SPONDYLITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE TORTUGA TRIAL (2021) (1)
Response to: ‘Correspondence on ‘MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group’’ by Jibri et al (2021) (1)
117 – Imaging in spondyloarthritis (2015) (1)
AB0524 EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES (2021) (1)
What's new on the sacroiliac joint ? (2021) (1)
Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors (2015) (1)
Observation by Magnetic Resonance Imaging of Sacroiliac Joint Ankylosis in Young Spondyloarthritis Patients Receiving Biologic Therapy: Comment on the Article by Bray et al (2019) (1)
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program (2021) (1)
Peripheral spondyloarthritis and psoriatic arthritis sine psoriase: are we dealing with semantics or clinically meaningful differences? (2022) (1)
[Differential diagnosis of back pain in patients with ankylosing spondylitis: instable cervical spine fracture]. (2012) (1)
[34-year-old patient with non-radiographic axial spondyloarthritis and acute back pain]. (2012) (0)
Do magnetic resonance training in spondyloarthritis improve the performance of rheumatologists for the recognition of sequences and lesions? (2020) (0)
Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis (2022) (0)
THU0352 Tofacitinib treatment is associated with attainment of the minimally important reduction in axial mri inflammation in patients with ankylosing spondylitis (2017) (0)
A214 A COMPARISON OF REAL-WORLD UTILIZATION PATTERNS OF INNOVATOR AND BIOSIMILAR INFLIXIMAB: A PRESCRIPTION CLAIMS DATA SUBGROUP ANALYSIS OF GERMAN GASTROENTEROLOGISTS (2018) (0)
AB1144 DAILY CLINICAL CARE OF PATIENTS WITH MUSCULOSKELETAL COMPLAINTS – HOW HELPFUL IS A TRIAGE SYSTEM FOR EARLY RECOGNITION OF INFLAMMATORY RHEUMATIC DISEASES? (2020) (0)
SAT0288 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline crp levels: pooled analysis of two phase 3 studies (2018) (0)
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination (2022) (0)
Facet Joint Involvement in Early MRI Positive Axial Spondyloarthritis (2022) (0)
Faculty Opinions recommendation of Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. (2013) (0)
THE IMPACT OF PERSISTENT INFLAMMATORY CHANGES ON PREVALENCE OF FAT LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: 4-YEAR MRI RESULTS FROM RAPID-axSpA (2021) (0)
POS0907 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (2021) (0)
Unanswered questions in the management of axial spondyloarthritis: an opinion piece. (2014) (0)
174 Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials (2018) (0)
Response to the comment by de Jongh et al on the article: Effects of anti-TNF-therapy on inflammatory, structural and osteoblastic activity lesions in radiographic axial spondyloarthritis. (2022) (0)
Janus kinase inhibitors modulate hepatitis E virus infection (2023) (0)
Hounsfield Units measured in low dose CT reliably assess vertebral trabecular bone density changes over two years in axial spondyloarthritis. (2022) (0)
Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis (2013) (0)
Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort. (2023) (0)
Acknowledgement to referees 2015 (2016) (0)
First Validation of Consensus Definitions for MRI Lesions in the Sacroiliac Joint By the Assessments in Spondyloarthritis International Society MRI Group (2018) (0)
Clinical Relevance of Axial Radiographic Damage in Axial Spondyloarthritis - Evaluation of Functional Consequences by an Objective Electronic Device. (2023) (0)
IL-17 INHIBITION : EMERGING PERSPECTIVES IN THE FUTURE MANAGEMENT OF AXIAL SPONDYLOARTHRITIS (2015) (0)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three (2017) (0)
THU0388 CLINICALLY RELEVANT DEFICITS IN PERFORMANCE TESTS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (AXSPA) - MORE THAN COLLECTING QUESTIONNAIRES NEEDS TO BE DONE (2019) (0)
[Frequency and severity of sarcopenia in patients with inflammatory and noninflammatory musculoskeletal diseases : Results of a monocentric study in a tertiary care center]. (2023) (0)
Faculty Opinions recommendation of Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. (2013) (0)
P225 Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patrients with RA: one-year outcomes from the select Phase 3 programme (2020) (0)
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis (2023) (0)
Reply to comment on: Changes in immunosuppressive medication because of COVID-19 by patients with chronic inflammatory rheumatic diseases: anxiety was not a major driver. (2022) (0)
Diagnostic Problems and Pitfalls (2012) (0)
SAT0257 A Major Clinical Response to Anti-TNF Agents is Associated with a Reduced Development of Fatty Changes in the Spine of Patients with Ankylosing Spondylitis – New Analyses from the Easic Registry (2013) (0)
Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario - The perception study. (2022) (0)
Proof-of-Concept Double-Blind Placebo-Controlled Trial Measuring Cartilage Composition in Early Rheumatoid Arthritis under TNF-α-Inhibitor Therapy (2023) (0)
Addressing the spread of health-related misinformation on social networks: an opinion article (2023) (0)
AB0691 CHARACTERIZATION OF DIFFERENT GROUPS WITH IMAGING AND NON-IMAGING FINDINGS OF ANKYLOSING SPONDYLITIS COMBINE WITH HIP LESION IN WESTERN CHINESE (2020) (0)
25385 Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analyses from phase III studies in psoriasis and psoriatic arthritis (PsA) (2021) (0)
[Are SARS-CoV-2 reactive T cells detectable and potentially protective in patients under anti-CD20 treatment with an impaired humoral response?] (2021) (0)
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis (2022) (0)
Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version (2021) (0)
OP0041 MRI Inflammation and Fat Deposition Both Contribute to Syndesmophyte Formation at the Same Site: A Multi-Level Analysis in Patients with Ankylosing Spondylitis (2015) (0)
Chapter 14 – Imaging in Ankylosing Spondylitis (2006) (0)
Spondyloarthritis@@@Spondyloarthritis: Interaktive Fälle zur aktuellen S3-Leitlinie „Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen“@@@Interactive cases according to the S3 guideline “Axial spondyloarthritis including Bechterew disease and early forms” (2016) (0)
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies (2023) (0)
POS0239 ROOT JOINT INVOLVEMENT IN SPONDYLOARTHRITIS: A POST-HOC ANALYSIS FROM THE INTERNATIONAL ASAS-PERSPA STUDY (2021) (0)
OP0320 SUCCESSFUL EVALUATION OF A PREDEFINED SET OF ANATOMIC SITES IN THE PELVIS OF PATIENTS WITH POLYMYALGIA RHEUMATICA SHOWING EXTRACAPSULAR INFLAMMATION AS VISUALIZED BY CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING: (2019) (0)
SAT0693 ONLINE EDUCATION SIGNIFICANTLY IMPROVED RHEUMATOLOGISTS’ UNDERSTANDING AND INTERPRETATION OF COMPARATIVE TREATMENT DATA FOR AS (2019) (0)
Effects of anti-TNF-therapy on inflammatory, structural and osteoblastic activity lesions in radiographic axial spondyloarthritis - a prospective proof-of-concept study using PET/MRI of SIJ and spine. (2022) (0)
Faculty Opinions recommendation of Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. (2008) (0)
[Multi-Faceted Symptoms with Joint Pain, Exanthema and Eye Involvement]. (2019) (0)
AB0968 DIAGNOSIS OF INFLAMMATORY BACK PAIN (IBP) IN A LOW-INCOME POPULATION USING ASAS IBP DEFINITION (2020) (0)
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials (2023) (0)
188 Real-world data on the use of certolizumab pegol for the treatment of axial spondyloarthritis in clinical practice in Europe: 24-week interim results from a prospective non-interventional cohort study (2018) (0)
SAT0563 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY IS EQUIVALENT TO MAGNETIC RESONANCE IMAGING IN THE EARLY DIAGNOSIS OF SPONDYLOARTHRITIS: A RETROSPECTIVE STUDY (2020) (0)
[Effect of multimodal rheumatologic complex treatment in patients with axial spondylarthritis : A systematic evaluation with standardized outcome parameters, such as the ASAS Health Index]. (2022) (0)
Faculty Opinions recommendation of Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. (2010) (0)
[Answering epidemiologic rheumatologic questions by cooperation with the large population-based SHIP cohort-findings with relevance for the diagnosis of axial spondyloarthritis (axSpA)]. (2021) (0)
Investigation of Patient Satisfaction with Education in a Biosimilar Multiswitch Scenario - A Comparison Between Rheumatologists and Nurse Specialists (2021) (0)
EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies (2020) (0)
FRI0385 LONG-TERM CERTOLIZUMAB PEGOL TREATMENT OF AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH RAPID AND SUSTAINED REDUCTION OF ACTIVE INFLAMMATION AND MINIMAL STRUCTURAL CHANGES IN THE SPINE: 4-YEAR MRI RESULTS FROM RAPID-AXSPA (2019) (0)
THU0235 The Role of C-Reactive Protein as a Predictor of Treatment Response in Patients with Ankylosing Spondylitis (2015) (0)
THU0526 MEASUREMENT OF RADIOLOGICAL JOINT WIDTH IS THE KEY IN ASSESSING HIP INVOLVEMENT OF HIPS IN ANKYLOSING SPONDYLITIS. (2020) (0)
SAT0635 Magnetic resonance imaging of the cervical spine in patients with rheumatoid arthritis and ankylosing spondylitis presenting with chronic neck pain – a systematic comparison of clinical assessments (2018) (0)
OP0225 DEPRESSIVE SYMPTOMS IN PSA: A CROSS-SECTIONAL ANALYSIS FROM THE NATIONAL GERMAN RABBIT-SPA REGISTRY (2021) (0)
Erratum to: New developments in Ankylosing spondylitis – Status in 2021 (2022) (0)
SP0195 IMAGING IN DISEASE AND TREATMENT MONITORING – DOES IT MATTER? (2019) (0)
AB0698 EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY (2019) (0)
Early Recognition and Treatment of Spondyloarthritis: A Timeless Challenge (2020) (0)
Inflammation, bone loss and 2-year bone formation at the same vertebra in axial spondyloarthritis: a multilevel MRI and low-dose CT analysis (2023) (0)
POS1145 PREVALENCE OF CHONDROCALCINOSIS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES – FREQUENTLY FOUND IN PATIENTS WITH RHEUMATOID ARTHRITIS AND VICE VERSA (2021) (0)
SAT0391 DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH HIGHER DISEASE ACTIVITY AND WORSE FUNCTIONAL STATUS IN AXSPA: A CROSS-SECTIONAL ANALYSIS FROM RABBIT-SPA (2020) (0)
SAT0365 EFFECTS OF ANTI-TNF-THERAPY ON OSTEOBLASTIC ACTIVITY IN ANKYLOSING SPONDYLITIS – RESULTS FROM A PROSPECTIVE STUDY USING PET-MRI OF SIJ AND SPINE (2020) (0)
SAT0384 REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPACT ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT? (2020) (0)
High prevalence of foot insufficiency fractures in patients with inflammatory rheumatic musculoskeletal diseases. (2022) (0)
The After 2 Years of Tumor Necrosis Factor Inhibitor Therapy Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes Vertebral Erosions Associated with Spinal Inflammation in Patients with (2013) (0)
Clinically Relevant Difference ? What Is the − − Classification and Diagnosis of Axial Spondyloarthritis (2014) (0)
THU0366 MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA – DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT (2019) (0)
Response to: ‘Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years’ by Parperis (2020) (0)
Diagnostic Value of the Anti-CD74 Antibodies for Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain. (2023) (0)
THU0223 Serum Biomarkers Associated with Changes in Asdas and MRI Following Treatment of Ankylosing Spondylitis with Golimumab (2015) (0)
POS0033 IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, BRIDGING SYNDESMOPHYTES INCREASE RISK OF FACET JOINT ANKYLOSIS ON THE SAME VERTEBRAL LEVEL WHILE FACET JOINT ANKYLOSIS DOES NOT INCREASE RISK OF SAME LEVEL SYNDESMOPHYTES (2021) (0)
Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis (2023) (0)
Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry (2023) (0)
POS0919 BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY (2021) (0)
Imaging Atlas of Axial Spondyloarthritis (2020) (0)
[EULAR points to consider: use of big data in rheumatic and musculoskeletal diseases]. (2020) (0)
Social Media Use Among Members of the Assessment of Spondyloarthritis International Society: Results of a Web-Based Survey (2023) (0)
The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study (2021) (0)
THU0367 ANALYSING IMPAIRMENTS IN PHYSICAL PERFORMANCE (AS ASSESSED BY THE AS PERFORMANCE INDEX (ASPI)) IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (2019) (0)
AB0684 LESS THAN 20% OF PATIENTS WITH A CHRONIC INFLAMMATORY RHEUMATIC DISEASE CHANGED THEIR IMMUNOSUPPRESSIVE MEDICATION BECAUSE OF THE COVID 19 PANDEMIC (2021) (0)
SAT0209 A comparative real-world utilization patterns of innovator and biosimilar infliximab in a treatment naÏve and switch population from germany: a prescription claims analysis (2018) (0)
Is contrast necessary to detect sacroiliitis on MRI in juvenile spondyloarthritis (2016) (0)
P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis (2021) (0)
AB0861 Relationship between disease duration and treatment response in patients with ankylosing spondylitis (AS) (2013) (0)
POS0055 SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY (2021) (0)
SAT0258 A Prospective Evaluation of the Diagnostic Value of Conventional Radiography, Ultrasound and MRI in Comparison to Clinical Examination for the Assessment of Heel and Knee Enthesitis in Patients With Spondyloarthritis and Controls (2013) (0)
Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals (2012) (0)
[Pain reduction by radiosynoviorthesis in rheumatism-induced synovitis of the elbow : Results of a retrospective multicenter data analysis]. (2022) (0)
Faculty Opinions recommendation of Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. (2011) (0)
FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis (2015) (0)
Drs. Baraliakos and Braun reply (2008) (0)
Evidence for a genetic contribution to the ossification of spinal ligaments in Ossification of Posterior Longitudinal Ligament and Diffuse idiopathic skeletal hyperostosis: A narrative review (2022) (0)
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS ORAL ABSTRACTS 1: SPONDYLOARTHROPATHIES (2012) (0)
260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis (2019) (0)
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY (2021) (0)
POS0584 ULTRASONOGRAPHY OF THE MEDIAN NERVE IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER SUSPICION OF CARPAL TUNNEL SYNDROME (2021) (0)
2020-2021 Board of Directors (2020) (0)
[How many patients with inflammatory rheumatic diseases have the technical prerequisites for video consultations and are also willing to use this to carry out visits by medical specialist visits?] (2021) (0)
Spondyloarthritis: The Changing Landscape Today (2020) (0)
SAT0564 EFFICACY OF ETANERCEPT OVER A PERIOD OF 12 MONTHS IN THE ROUTINE TREATMENT OF PATIENTS WITH RA, AXSPA, PSA OR PSO: FINAL RESULTS OF A GERMAN NON-INTERVENTIONAL, PROSPECTIVE, MULTI-CENTER STUDY (ADEQUATE) (2019) (0)
Acknowledgement to referees (2016) (0)
SAT0579 SYSTEMATIC GERIATRIC ASSESSMENT IN OLDER PATIENTS WITH RHEUMATIC DISEASES - THE RheuMAGIC PILOT STUDY (2020) (0)
FRI0386 RELATIONSHIP BETWEEN ASDAS STATES AND INHIBITION OF STRUCTURAL DAMAGE PROGRESSION WITH SECUKINUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM MEASURE 1 TRIAL (2019) (0)
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE (2019) (0)
Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA (2023) (0)
25529 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: Updated pooled safety analyses (2021) (0)
AB0471 PATIENTS WITH RADIOGRAPHIC axSpA WHO PROGRESSED FROM ASAS20 AT WEEK 16 TO ASAS40 AT WEEK 52: RESULTS FROM COAST-W (2021) (0)
SAT0310 IDENTIFICATION OF FACTORS ASSOCIATED WITH MAGNETIC RESONANCE IMAGES CHANGES SUGGESTIVE OF AXIAL SPONDYLOARTHRITIS IN THE AXIAL SKELETON OF INDIVIDUALS <45 YEARS – EVALUATION OF DATA FROM A LARGE COMMUNITY STUDY (2019) (0)
Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study (2020) (0)
THU0359 WHAT IS THE LEVEL OF AGREEMENT BETWEEN LOCAL AND CENTRAL READERS IN THE DETECTION OF ACTIVE AND STRUCTURAL LESIONS ON MRI TYPICAL OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY (2019) (0)
THU0614-HPR ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS (2020) (0)
Prevalence of Inflammatory Back Pain in a Low-Income Population (2022) (0)
246 Safety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study (2019) (0)
P134 Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from two Phase 3 Studies (2023) (0)
SAT0316 EARLY RECOGNITION OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS BY USING A PRACTICAL REFERRAL SYSTEM – EVALUATION OF THE RECENTLY PROPOSED 2-STEP STRATEGY (2019) (0)
What is the best referral strategy for axial spondyloarthritis? A prospective multicenter study in patients with suspicious chronic low back pain. (2023) (0)
Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis (2022) (0)
E098 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542) (2019) (0)
Targeted therapies: TNF-α blockers in the treatment of spondyloarthritis (2013) (0)
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging (2022) (0)
THU0398 Secukinumab sustains individual clinical responses over time in patients with active ankylosing spondylitis: 2-year results from a phase 3 trial, measure 2 (2017) (0)
FRI0521 EARLY RECOGNITION OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS BY USING A PRACTICAL REFERRAL SYSTEM – EVALUATION OF THE RECENTLY PROPOSED 2-STEP STRATEGY (2020) (0)
262 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies (2019) (0)
[Guidelines "Gender-neutral language in the German Society for Rheumatology (DGRh e.V.)"]. (2022) (0)
Message from the new EULAR President and Steering Group (2021) (0)
Reply to: Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment? (2019) (0)
FRI0306 WOMEN WITH AXIAL SPONDYLOARTHRITIS HAVE COMPARABLE RATES OF COMPLICATIONS IN PREGNANCY TO WOMEN IN THE GENERAL POPULATION BUT MORE CAESAREAN DELIVERIES: RESULTS FROM NATIONWIDE CLAIMS DATA (2020) (0)
Deep Learning Detects Changes Indicative of Axial Spondyloarthritis at MRI of Sacroiliac Joints. (2023) (0)
SAT0437 GENDER DIFFERENCES IN PsA OUTCOME PARAMETERS AND THEIR CORRELATION WITH SKIN INVOLVEMENT: A CROSS-SECTIONAL ANALYSIS OF RABBIT-SpA PAtients (2020) (0)
AB0472 DISEASE ACTIVITY AND OUTCOME IN PREGNANCIES OF PATIENTS WITH SpA - DATA FROM THE GERMAN PREGNANCY REGISTER RHEKISS (2021) (0)
Treating to Target in Clinical Practice: The Results of a Questionnaire Completed by Greek Rheumatologists (2020) (0)
AB0758 Performance of a therapeutic attempt with oral prednisolone in patients with rheumatoid arthritis and hand osteoarthritis – a proof of concept study (2013) (0)
Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls (2021) (0)
Patients with Active Ankylosing Spondylitis Treated with Golimumab Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in (2016) (0)
OP0249 The contribution of structural mri lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort (2018) (0)
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS) (2019) (0)
SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD (2022) (0)
Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review (2019) (0)
POS0038 THE INFLUENCE OF AGE ON THE PREVALENCE OF INFLAMMATORY AND POST-INFLAMMATORY MRI LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AND WITHOUT AXIAL SPONDYLOARTHRITIS (2021) (0)
[Rheumatology training positions in Germany]. (2022) (0)
Patients´ awareness towards physical activity in the treatment of axial spondyloarthritis. (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Xenofon Baraliakos?

Xenofon Baraliakos is affiliated with the following schools:

University of Cologne
Ruhr University Bochum